Memo Therapeutics (spinoff from ETH Zurich) is using its proprietary MemoMABé technology to develop a therapeutic antibody pipeline targeting infectious diseases, cancer and immune mediated inflammatory diseases (IMID).
Memo Therapeutics AG
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/memo-therapeutics-ag” connections=”true” suffix=””]
Memo Therapeutics proprietary MemoMABé platform drives the companys proprietary antibody and target discovery, and is made available to partners and clients in the industry as well as for selected projects with academia.
In July 2015, Memo Therapeutics raised 2.3 Mn Swiss Francs in a series A round, from investors including EVA Basel, Redalpine Venture Partners and Zu?rcher Kantonalbank.